Zevra Therapeutics Q3 EPS $(0.40) Misses $(0.30) Estimate, Sales $2.90M Miss $3.38M Estimate
Author: Benzinga Newsdesk | November 07, 2023 08:02am
Zevra Therapeutics (NASDAQ:
ZVRA) reported quarterly losses of $(0.40) per share which missed the analyst consensus estimate of $(0.30) by 33.33 percent. This is a 110.53 percent decrease over losses of $(0.19) per share from the same period last year. The company reported quarterly sales of $2.90 million which missed the analyst consensus estimate of $3.38 million by 14.35 percent. This is a 0.73 percent increase over sales of $2.87 million the same period last year.
Posted In: ZVRA